<DOC>
	<DOCNO>NCT00004920</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether receive cisplatin raltitrexed effective cisplatin alone malignant mesothelioma . PURPOSE : Randomized phase III trial compare effectiveness cisplatin without raltitrexed treat patient malignant mesothelioma pleura .</brief_summary>
	<brief_title>Cisplatin With Without Raltitrexed Treating Patients With Malignant Mesothelioma Pleura</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient malignant pleural mesothelioma treat raltitrexed without cisplatin . - Assess toxicity , progression free survival , quality life treatment regimens patient . - Evaluate objective response duration response treatment regimens patient measurable disease . OUTLINE : This randomize , open , multicenter study . Patients stratify accord performance status ( 0 vs 1-2 ) WBC count ( le 8,300/mm3 v 8,300/mm3 ) . Patients randomize one two treatment arm . - Arm I : Patients receive cisplatin IV 1-2 hour day 1 . - Arm II : Patients receive raltitrexed IV 15 minute follow cisplatin IV 1-2 hour day 1 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Quality life assess study , prior course , last course , every 6 week 1 year . Patients follow every 6 week death . PROJECTED ACCRUAL : A total 240 patient accrue study 24 month .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant pleural mesothelioma No CNS metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ZUBROD , ECOG , WHO 02 Life expectancy : Not specify Hematopoietic : Hemoglobin least 10.0 g/dL WBC least 4,000/mm^3 Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.46 mg/dL Albumin least 3.0 g/dL ALAT/ASAT le 2.5 time upper limit normal ( ULN ) ( less 5 time ULN liver involvement ) Renal : Creatinine le 1.69 mg/dL Creatinine clearance least 65 mL/min Cardiovascular : Not specify Pulmonary : Not specify Other : No prior concurrent malignancy within past 5 year except adequately treat carcinoma situ cervix basal squamous cell carcinoma skin No prior malignant melanoma , hypernephroma breast carcinoma Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No uncontrolled infection No psychological , familial , sociological , geographical condition precludes study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy first disease progression Chemotherapy : No prior systemic intracavitary cytotoxic chemotherapy No prior concurrent chemotherapy first disease progression No prior concurrent pleurodesis cytotoxic drug ( e.g. , bleomycin ) Endocrine therapy : No concurrent hormonal therapy except corticosteroid first disease progression Radiotherapy : At least 4 week since prior radiotherapy target lesion progression observe Concurrent palliative radiotherapy painful lesion allow target lesion outside irradiated field Surgery : Prior surgery allow followed disease progression Other : At least 1 month since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>